Studies

69 studies · Download as JSON

• A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress PyroptosisAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit · Unreviewed automatic assessment
• GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective reviewCase-control · 2026 · Study tier 4 · Different population · Null · Unreviewed automatic assessment
• Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With ObesityRetrospective cohort · 2026 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian RandomizationMendelian randomization · 2026 · Study tier 3 · Population unclear · Harm direction · Unreviewed automatic assessment
• Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose TissueAnimal study · 2026 · Study tier 4 · Not human evidence · Unclear · Unreviewed automatic assessment
• Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Population unclear · Null · Unreviewed automatic assessment
• Liraglutide Attenuates Hepatocyte Ferroptosis in an In Vitro Model of Metabolic Dysfunction-Associated Steatotic Liver DiseaseCell / in-vitro · 2026 · Study tier 4 · Not human evidence · Benefit · Unreviewed automatic assessment
• Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• GLP1-RA Use and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 DiabetesRetrospective cohort · 2026 · Study tier 3 · Different population · Harm direction · Unreviewed automatic assessment
• Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Liraglutide Attenuates Multiorgan Oxidative, Astroglial, and Mitochondrial Stress Responses in Thioacetamide-Induced Hepatic EncephalopathyAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit · Unreviewed automatic assessment
• Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic ReviewSystematic review · 2026 · Study tier 2 · Population unclear · Mixed · Unreviewed automatic assessment
• FDA prescribing information: Ozempic (SEMAGLUTIDE) - label effective 2026-07-30Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2026-07-27Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Partly industry funded · Unreviewed automatic assessment
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2026-06-16Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trialsMeta-analysis · 2026 · Study tier 2 · Partial match · Null
• FDA prescribing information: OZEMPIC, RYBELSUS (ORAL SEMAGLUTIDE) - label effective 2026-01-30Regulatory document · 2026 · Not rated · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2026-01-30Regulatory document · 2026 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialRandomized trial · 2026 · Study tier 3 · Partial match · Mixed · Partly industry funded
• Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance databasePharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 3 · Population unclear · Harm direction · Unreviewed automatic assessment
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2025-11-13Regulatory document · 2025 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2025-10-16Regulatory document · 2025 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trialRandomized trial · 2025 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetesRandomized trial · 2025 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2025-01-30Regulatory document · 2025 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsMeta-analysis · 2025 · Study tier 1 · Different population · Benefit
• Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysisMeta-analysis · 2025 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patientsRandomized trial · 2024 · Study tier 3 · Population unclear · Null · Unreviewed automatic assessment
• Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical TrialRandomized trial · 2024 · Study tier 2 · Different population · Harm direction · Partly industry funded
• Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysisMeta-analysis · 2024 · Study tier 2 · Population unclear · Unclear · Unreviewed automatic assessment
• FDA prescribing information: WEGOVY (SEMAGLUTIDE) - label effective 2024-04-23Regulatory document · 2024 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical TrialRandomized trial · 2024 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept StudyRandomized trial · 2024 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trialRandomized trial · 2024 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2023-12-12Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2023-12-09Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: Ozempic (SEMAGLUTIDE) - label effective 2023-11-22Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• FDA prescribing information: OZEMPIC (SEMAGLUTIDE) - label effective 2023-11-17Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossRetrospective cohort · 2023 · Study tier 3 · Different population · Harm direction
• FDA prescribing information: TRULICITY (DULAGLUTIDE) - label effective 2023-08-05Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double‑blind, randomized controlled clinical trialRandomized trial · 2023 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• FDA prescribing information: TRULICITY (DULAGLUTIDE) - label effective 2023-05-03Regulatory document · 2023 · Not rated · Population unclear · Null · Not peer reviewed · Unreviewed automatic assessment
• Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trialRandomized trial · 2023 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trialRandomized, parallel-group, quadruple-blind (drug arms), placebo-controlled trial; 3 arms (liraglutide, hypocaloric diet, sitagliptin) in 2:1:1 ratio; 14 weeks; measurements at baseline, 2 weeks (pre-weight-loss), and 14 weeks. · 2023 · Study tier 3 · Different population · Mixed
• Proinflammatory biomarkers are associated with prediabetes in patients with schizophreniaRandomized trial · 2022 · Study tier 3 · Different population · Null · Unreviewed automatic assessment
• Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trialRandomized trial · 2022 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trialsMeta-analysis · 2022 · Study tier 2 · Population unclear · Unclear · Unreviewed automatic assessment
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit
• Effect of liraglutide on expression of inflammatory genes in type 2 diabetesRandomized trial · 2021 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trialDesign unknown · 2021 · Not rated · Population unclear · Unclear · Unreviewed automatic assessment
• Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both CombinedRandomized trial · 2021 · Study tier 2 · Different population · Benefit · Partly industry funded
• Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trialsMeta-analysis · 2020 · Study tier 2 · Population unclear · Mixed · Unreviewed automatic assessment
• Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathyRandomized trial · 2019 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trialCrossover trial · 2019 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathyMeta-analysis · 2019 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight LossRandomized trial · 2018 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2017 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trialCrossover trial · 2017 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trialRandomized trial · 2017 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunctionRandomized trial · 2017 · Study tier 3 · Different population · Null · Unreviewed automatic assessment
• Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesRandomized trial · 2016 · Study tier 1 · Different population · Benefit · Partly industry funded
• Benefits of liraglutide treatment in overweight and obese older individuals with prediabetesRandomized trial · 2013 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular functionRandomized trial · 2012 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment